Precision BioSciences Inc (DTIL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $277.88M
Last updated: Nov 17, 2026 at 4:10 PM ET
Precision BioSciences Inc (DTIL) Statistics
Precision BioSciences (DTIL) has a market cap of $277.88M and an enterprise value of $218.61M. Revenue grew 6353.01% over the last 12 months from the 12 months before. Its share count is up 132.13% from a year earlier.
Total Valuation
Enterprise value is 21.33% below the market cap, as cash exceeds debt.
| Market Cap | $277.88M |
|---|---|
| Enterprise Value | $218.61M |
| Latest price (Nov 17, 2026) | $7.05 |
Key Dates
The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 10, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 3, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.3x and 3.7x. Its year-end P/S ranged from 0.4x to 31.5x from 2019 to 2025.
| P/S Ratio | 4.3x |
|---|---|
| Forward P/S | 24.5x |
| P/B Ratio | 3.7x |
| P/TBV Ratio | 3.8x |
Price Statistics
The stock is up 19.90% over 52 weeks and trades 0.57% above its 50-day average.
| Beta (1Y) | 0.43 |
|---|---|
| 52-Week Change | +19.90% |
| 1-Month Change | +13.89% |
| 3-Month Change | -17.06% |
| 6-Month Change | +2.17% |
| 5-Year Change | -97.52% |
| Total Return (1Y) | +19.90% |
| Total Return (3Y CAGR) | -18.65% |
| Total Return (5Y CAGR) | -51.93% |
| Return vs SPY (1Y) | +23.50% |
| Max Drawdown (1Y) | -37.82% |
| Max Drawdown (3Y) | -80.77% |
| Sharpe Ratio (1Y) | 0.41 |
| Correlation with SPY (1Y) | 0.08 |
| 50-Day Average | $7.01 |
| 200-Day Average | $6.80 |
| 52-Week Range | $3.53 to $11.29 |
| RSI (14 Days) | 44.7 |
| Average Volume (20 Days) | 447.59K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 10.47x current liabilities, and total debt is 0.43x shareholder equity.
| Current Ratio | 10.47x |
|---|---|
| Quick Ratio | 10.47x |
| Debt / Equity | 0.43x |
| Interest Coverage | 1.84x |
Returns and Efficiency
Return on invested capital is -38.29% over the last 12 months, against a 5-year average of -57.52%.
| Return on Equity (ROE) | -74.45% |
|---|---|
| Return on Assets (ROA) | -32.02% |
| Return on Invested Capital (ROIC) | -38.29% |
| Return on Capital Employed (ROCE) | -32.08% |
| ROA (5Y Average) | -24.82% |
| ROIC (5Y Average) | -57.52% |
| Asset Turnover | 0.42x |
Scores
DTIL has an Altman Z-Score of -4.96, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -4.96 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $45.04M over the last 12 months.
| Revenue | $45.04M |
|---|---|
| Revenue Growth (YoY) | +6353.01% |
| Gross Profit | $45.04M |
| Operating Income | -$36.16M |
| Pretax Income | -$39.00M |
| Net Income | -$38.55M |
| EBITDA | -$33.32M |
| EBIT | -$35.96M |
| Reported EPS (TTM) | -$1.10 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 43.01% of the $120.38M in total assets.
| Cash and Equivalents | $81.70M |
|---|---|
| Total Debt | $22.42M |
| Net Cash | $59.27M |
| Net Cash Per Share | $2.16 |
| Working Capital | $78.31M |
| Shareholder Equity | $51.77M |
| Book Value Per Share | $1.89 |
| Tangible Book Value | $50.71M |
| Tangible Book Per Share | $1.85 |
| Total Assets | $120.38M |
| Total Liabilities | $68.60M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$51.76M |
|---|---|
| FCF Per Share | -$1.88 |
| Depreciation and Amortization | $2.64M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -80.27%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -80.27% |
| Pretax Margin | -86.59% |
| Net Margin | -85.58% |
| EBITDA Margin | -73.97% |
| EBIT Margin | -79.84% |
Growth
Revenue grew 10.93% a year over 3 years.
| Revenue Growth (3Y CAGR) | +10.93% |
|---|---|
| Revenue Growth (5Y CAGR) | +7.13% |
| Book Value Per Share Growth (2Y CAGR) | +6.58% |
| Tangible Book Per Share Growth (2Y CAGR) | +7.04% |
Dividends and Yields
DTIL does not pay a dividend.
| Buyback Yield | -46.03% |
|---|---|
| Shareholder Yield | -46.03% |
Stock Splits
The last split was a 1-for-30 reverse split on Feb 14, 2024.
| Last Split Date | Feb 14, 2024 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Peer Position
Against 9 similar companies, DTIL has the 8th highest P/S.
P/S RatioPeer median 8.1x
ROICPeer median -42.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +9.35%
| P/S Ratio | 4.3x vs 8.1x median |
|---|---|
| ROIC | -38.29% vs -42.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +6353.01% vs +9.35% median |
Analyst Forecast
Consensus estimates put revenue growth at -49.49% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -49.49% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About DTIL
What is DTIL's market cap?
Precision BioSciences has a market cap of $277.88M. Its enterprise value, which adds debt and subtracts cash, is $218.61M.
How many shares of DTIL are outstanding?
Precision BioSciences has 27.43M shares outstanding. The count is up 132.13% from a year earlier.
Does DTIL pay a dividend?
No. Precision BioSciences does not pay a dividend.
How much debt does DTIL have?
Precision BioSciences has $22.42M of total debt and $81.70M of cash and equivalents, a net cash position of $59.27M.
DTIL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors